Načítá se...
Bone and renal safety profile at 72 weeks after switching to tenofovir alafenamide in chronic hepatitis B patients
BACKGROUND AND AIM: Tenofovir disoproxil fumarate (TDF) has been efficacious in treating chronic hepatitis B (CHB), but long‐term use is accompanied by a decline in renal function and bone mineral density (BMD). Tenofovir alefanamide (TAF) is a prodrug of tenofovir, with similar efficacy in CHB but...
Uloženo v:
| Vydáno v: | JGH Open |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Wiley Publishing Asia Pty Ltd
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7857293/ https://ncbi.nlm.nih.gov/pubmed/33553665 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jgh3.12481 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|